Evidence map›Paper›PMID 41035662›Full record

ArticleFrontiers in oncology2025

Machine learning-based analysis identifies glucose metabolism-related genes ADPGK as potential diagnostic biomarkers for clear cell renal cell carcinoma.

Tie Li, Shijin Wang, Guandu Li, Xiaochen Qi, Guangzhen Wu, Xiangyu Che

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tie Li *Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Shijin Wang *Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Guandu Li *Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Xiaochen QiDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Guangzhen WuDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Xiangyu CheDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Clear cell renal cell carcinoma, with its high morbidity and mortality, is one of the more difficult diseases in the world and still lacks an effective therapeutic target. The primary way they break down glucose is through aerobic glycolysis, which leads to energy acquisition and synthesis of the material base required for cell growth. Although targeting glucose metabolism has driven the development of a variety of tumour therapies, the specific regulatory mechanisms remain unclear. Therefore, based on machine learning analysis algorithms, we analysed the correlation between glycometabolic pathways and ccRCC in the REACTOME database and verified the impact of the key gene Methods: We utilised a total of 89 gene collections of glucose metabolism pathways from the REACTOME (https://reactome.org/) database as the data base for our study. To uncover potential therapeutic target genes, we adopt three machine learning algorithms (LASSO, RF, and Boruta). We reassigned the 7 screened genes based on gene expression differences between cancer and paracancerous tissues, and applied an unsupervised consensus clustering algorithm to establish a typology based on the expression of glucose metabolism-related genes ( Results: We identified Discussion: Our results suggest that targeting the glucose metabolism pathway can kill ccRCC cells.

Indexed as

ADP-dependent glucokinase (ADPGK)clear cell renal cell carcinoma (ccRCC)glucose metabolismimmune infiltrationmachine learning

Identifiers

PMID41035662
PMCPMC12479329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.